Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
64.13
-2.24 (-3.38%)
At close: Aug 25, 2025, 4:00 PM
64.40
+0.27 (0.42%)
After-hours: Aug 25, 2025, 5:30 PM EDT
Cidara Therapeutics Revenue
In the year 2024, Cidara Therapeutics had annual revenue of $1.28M, down -94.52%.
Revenue (ttm)
$1.28M
Revenue Growth
-94.52%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
1.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28M | -22.01M | -94.52% |
| Dec 31, 2023 | 23.28M | -213.00K | -0.91% |
| Dec 31, 2022 | 23.50M | -26.08M | -52.60% |
| Dec 31, 2021 | 49.57M | 37.51M | 310.81% |
| Dec 31, 2020 | 12.07M | -8.85M | -42.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CDTX News
- 10 days ago - Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout - Seeking Alpha
- 17 days ago - Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 - GlobeNewsWire
- 7 weeks ago - Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Business Wire
- 7 weeks ago - Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 2 months ago - Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 2 months ago - Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire